GBS Venture Partners

Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

Elastagen is a clinical stage medical company focused on developing products derived from the human protein tropoelastin, which is essential for the elasticity and resilience of various tissues in the body, including skin and blood vessels. The company has created a synthetic version of elastin that mimics the natural protein found in humans. Its advanced product pipeline targets applications in skin rejuvenation, scar remodeling, and tissue repair. With injectable synthetic human elastin and chemically cross-linked tropoelastin for aesthetic uses, Elastagen aims to help patients maintain skin elasticity and suppleness. Founded after acquiring intellectual property rights to elastin technology developed by Professor Weiss at the University of Sydney, Elastagen has successfully secured funding from prominent life science venture capital firms and expanded its operations to include production in Europe and clinical activities in the UK.

Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company specializes in a minimally invasive intracanalicular scaffold that alleviates high intraocular pressure by restoring the natural outflow pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its primary focus on glaucoma, Ivantis intends to explore innovative treatments for other ophthalmic diseases as it expands its product offerings. The company also provides a Session Persistence Server to support clinical trials, ensuring data protection for telnet task workers and terminal emulation users across various devices and operating systems.

AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Neurovance, Inc. is a clinical-stage neuroscience company based in Cambridge, Massachusetts, that specializes in developing therapies for attention deficit hyperactivity disorder (ADHD) in both adults and children. Founded in 2009, the company focuses on centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine, dopamine, and serotonin to improve focus and reduce inattention and disorganization in ADHD patients. As of March 31, 2017, Neurovance operates as a subsidiary of Otsuka America, Inc., and has received venture capital funding from various investors, including Novartis Venture Fund and the State of Wisconsin Investment Board.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company specializes in a minimally invasive intracanalicular scaffold that alleviates high intraocular pressure by restoring the natural outflow pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its primary focus on glaucoma, Ivantis intends to explore innovative treatments for other ophthalmic diseases as it expands its product offerings. The company also provides a Session Persistence Server to support clinical trials, ensuring data protection for telnet task workers and terminal emulation users across various devices and operating systems.

AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

Hydrexia is an Australian company that has successfully designed, built, and tested systems that stores hydrogen in solid form, based on a proprietary magnesium alloy.

Neurovance, Inc. is a clinical-stage neuroscience company based in Cambridge, Massachusetts, that specializes in developing therapies for attention deficit hyperactivity disorder (ADHD) in both adults and children. Founded in 2009, the company focuses on centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine, dopamine, and serotonin to improve focus and reduce inattention and disorganization in ADHD patients. As of March 31, 2017, Neurovance operates as a subsidiary of Otsuka America, Inc., and has received venture capital funding from various investors, including Novartis Venture Fund and the State of Wisconsin Investment Board.

Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications. Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.

Hatchtech is an Australian company focused on developing innovative pest control solutions through its proprietary technology platform. The company's patented approach targets the egg hatch of pest species, effectively disrupting their lifecycle with a novel mode of action. Hatchtech's technology is designed to address various invertebrate pests, including ectoparasites such as head lice, as well as pests affecting animals, crops, and the built environment. Their flagship product offers a single-dose treatment that eliminates both head lice and their eggs in one application, providing an effective solution for infestations.

AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

Celladon Corporation is a biotechnology company focused on developing molecular therapies for the treatment of heart failure. Founded in 2000 and headquartered in La Jolla, California, the company is known for its product candidates that address key enzyme deficiencies associated with advanced heart failure. One of its primary products, SERCA2a, is an enzyme that plays a crucial role in calcium cycling and contractility in heart muscle cells. Additionally, Celladon is developing MYDICAR, an enzyme replacement therapy aimed at improving heart function in patients suffering from heart failure.

AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

Xenome is a progressive Australian biotechnology company with a promising and distinctive technology platform targeting pain and inflammation. Xen2174, the Company's lead drug candidate is currently completing a Phase 1b/2a clinical trial for cancer pain with evidence to date providing strong support that the trial endpoints will be successfully met. More substantive clinical trials for expanded indications are planned for 2008. In addition, the drug discovery platform from which Xen2174 emerged has inherent value due to its ability to repeatedly identify new lead medicinal compounds on the basis of its unique construction around Australian biodiversity. Specifically, Xenome has generated a unique expertise in peptide chemistry to translate the evolutionary advantages inherent in venom peptides into highly bioactive libraries of molecules that are of interest to global biotechnology and pharmaceutical companies.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.

Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined product portfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need. Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.

Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications. Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.

Euthymics Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for central nervous system disorders. Established in 2009, the company is dedicated to addressing significant unmet medical needs, particularly in major depressive disorder (MDD) and alcohol use disorder (AUD). Euthymics is advancing its lead product, EB-1010, aimed at improving treatment outcomes for patients with depression who do not respond adequately to standard therapies such as selective serotonin reuptake inhibitors (SSRIs). This treatment seeks to enhance efficacy while minimizing common side effects associated with traditional antidepressants, including weight gain and sexual dysfunction. Additionally, Euthymics is exploring therapeutic options for smoking cessation and impulsivity, targeting withdrawal symptoms and cravings in affected individuals.

AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

Hatchtech is an Australian company focused on developing innovative pest control solutions through its proprietary technology platform. The company's patented approach targets the egg hatch of pest species, effectively disrupting their lifecycle with a novel mode of action. Hatchtech's technology is designed to address various invertebrate pests, including ectoparasites such as head lice, as well as pests affecting animals, crops, and the built environment. Their flagship product offers a single-dose treatment that eliminates both head lice and their eggs in one application, providing an effective solution for infestations.

AiMedics is a medical device company focused on developing solutions for managing hypoglycemia, particularly during the night. Its primary product, the HypoMon, is a non-invasive alarm system designed to detect nighttime hypoglycemia in children and young adults aged 10 to 25 with type 1 diabetes. This device alerts both patients and their caregivers, helping to improve safety and health outcomes. AiMedics serves a diverse clientele, including caregivers, patients, and healthcare professionals across the United States, Europe, Australia, and New Zealand. Founded in 2001, the company is headquartered in Eveleigh, Australia, and maintains an additional office in Warwick, United Kingdom.

NeuroVista Corporation is a medical device company based in Seattle, Washington, focused on developing innovative technologies for the management and treatment of epilepsy, a condition impacting approximately 3 million individuals in the United States. The company provides advisory technologies designed to reduce the uncertainty surrounding the onset of epileptic seizures, which can vary in severity from brief lapses of awareness to severe convulsions. Founded in 2002 and originally known as BioNeuronics Corporation, NeuroVista rebranded in 2007 to emphasize its commitment to addressing the challenges faced by those affected by epilepsy, a neurological disorder that predominantly affects individuals aged 15 to 64.

Nuon Therapeutics is focused on the development and commercialization of new therapies in inflammation and neurological diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and neuropathic pain.

Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.

Euthymics Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for central nervous system disorders. Established in 2009, the company is dedicated to addressing significant unmet medical needs, particularly in major depressive disorder (MDD) and alcohol use disorder (AUD). Euthymics is advancing its lead product, EB-1010, aimed at improving treatment outcomes for patients with depression who do not respond adequately to standard therapies such as selective serotonin reuptake inhibitors (SSRIs). This treatment seeks to enhance efficacy while minimizing common side effects associated with traditional antidepressants, including weight gain and sexual dysfunction. Additionally, Euthymics is exploring therapeutic options for smoking cessation and impulsivity, targeting withdrawal symptoms and cravings in affected individuals.

Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

Viveve is a women's sexual health company that specializes in non-surgical treatments aimed at addressing issues related to vaginal looseness and loss of sensation, which can occur after childbirth. The company has developed the Viveve System, a medical technology that employs cryogen-cooled monopolar radiofrequency technology to restore collagen fibers that may have been overstretched or damaged during delivery. This system is designed for non-invasive treatments of vaginal laxity, sexual function enhancement, vaginal rejuvenation, and stress urinary incontinence. Founded in 2005 and based in Palo Alto, California, Viveve operates in multiple regions, including the United States, Asia Pacific, Canada, Europe, the Middle East, and Latin America, and markets its products for various surgical applications.

Xenome is a progressive Australian biotechnology company with a promising and distinctive technology platform targeting pain and inflammation. Xen2174, the Company's lead drug candidate is currently completing a Phase 1b/2a clinical trial for cancer pain with evidence to date providing strong support that the trial endpoints will be successfully met. More substantive clinical trials for expanded indications are planned for 2008. In addition, the drug discovery platform from which Xen2174 emerged has inherent value due to its ability to repeatedly identify new lead medicinal compounds on the basis of its unique construction around Australian biodiversity. Specifically, Xenome has generated a unique expertise in peptide chemistry to translate the evolutionary advantages inherent in venom peptides into highly bioactive libraries of molecules that are of interest to global biotechnology and pharmaceutical companies.

Nuon Therapeutics is focused on the development and commercialization of new therapies in inflammation and neurological diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and neuropathic pain.

Nuwellis is a medical device company dedicated to enhancing the lives of individuals affected by fluid overload. They specialize in two key products: the Aquadex SmartFlow System and RenalSense Clarity RMS. The Aquadex system gently removes excess fluid from patients who have not responded to other treatments, while the Clarity RMS continuously monitors kidney function, displaying real-time data to healthcare professionals.

Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.

Founded in 2004, Applied Physiology develops and commercializes treatment guidance systems intended to transform the care of critically-ill patients. The company's main focus is on real-time circulation management with its Navigator™ product. Applied Physiology has offices in Australia and the United Kingdom.

Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined product portfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need. Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.

Humanigen, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, that specializes in the development of proprietary monoclonal antibodies aimed at immunotherapy and oncology treatments. The company’s leading candidate, Lenzilumab, targets granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I portion of a Phase I/II clinical trial for various hematologic malignancies. The company is also working on HGEN005, an anti-EMR1 monoclonal antibody in the pre-clinical stage for eosinophilic diseases. Humanigen has established collaborations, including a clinical partnership with Kite Pharma to study Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma and a research agreement with the Department of Defense to facilitate the development of Lenzilumab for potential emergency use in COVID-19. Formed in 2000, the company was previously known as KaloBios Pharmaceuticals and rebranded as Humanigen in 2017.

Humanigen, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, that specializes in the development of proprietary monoclonal antibodies aimed at immunotherapy and oncology treatments. The company’s leading candidate, Lenzilumab, targets granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I portion of a Phase I/II clinical trial for various hematologic malignancies. The company is also working on HGEN005, an anti-EMR1 monoclonal antibody in the pre-clinical stage for eosinophilic diseases. Humanigen has established collaborations, including a clinical partnership with Kite Pharma to study Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma and a research agreement with the Department of Defense to facilitate the development of Lenzilumab for potential emergency use in COVID-19. Formed in 2000, the company was previously known as KaloBios Pharmaceuticals and rebranded as Humanigen in 2017.

KaloBios Pharmaceuticals provides medicines for respiratory diseases and certain cancers. The company is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases. They designed to overcome marketed antibody products.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Peplin is a development-stage specialty pharmaceutical company that focuses on advancing and commercializing medical dermatology products. The company's lead product candidate is PEP005, a patient-applied topical gel derived from the plant Euphorbia peplus, designed to treat actinic keratosis. PEP005 is currently in Phase III clinical trials. In addition to this, Peplin is also developing a physician-applied formulation of PEP005 for the treatment of superficial basal cell carcinoma. The active compound in both formulations is a small molecule extracted and purified from the sap of Euphorbia peplus. Peplin further expanded its capabilities in the dermatology sector by acquiring Neosil, Inc. in 2008, and was subsequently acquired by LEO Pharma A/S.

Xenome is a progressive Australian biotechnology company with a promising and distinctive technology platform targeting pain and inflammation. Xen2174, the Company's lead drug candidate is currently completing a Phase 1b/2a clinical trial for cancer pain with evidence to date providing strong support that the trial endpoints will be successfully met. More substantive clinical trials for expanded indications are planned for 2008. In addition, the drug discovery platform from which Xen2174 emerged has inherent value due to its ability to repeatedly identify new lead medicinal compounds on the basis of its unique construction around Australian biodiversity. Specifically, Xenome has generated a unique expertise in peptide chemistry to translate the evolutionary advantages inherent in venom peptides into highly bioactive libraries of molecules that are of interest to global biotechnology and pharmaceutical companies.

Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.

NovaSys Health is a prominent provider of managed healthcare services, operating one of the largest health plans in Arkansas. With approximately 11,000 contracted providers in the region and over 4,300 in Arkansas, the company emphasizes strong relationships with healthcare providers. It offers a range of health plans and related services, including customized solutions, provider relations, and eligibility and billing administration, catering to a diverse network of hospitals, physicians, and ancillary providers.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Nuon Therapeutics is focused on the development and commercialization of new therapies in inflammation and neurological diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and neuropathic pain.

As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.

ChemGenex Pharmaceuticals Ltd is a biopharmaceutical development company focused on discovering and developing innovative oncology drugs. Founded in 1958 and headquartered in Geelong, Australia, the company is engaged in the development of small molecules aimed at addressing significant unmet medical needs in cancer treatment. Its lead product candidate, omacetaxine mepesuccinate, is an investigational agent currently undergoing Phase 2/3 clinical trials for chronic myelogenous leukemia, as well as Phase 2 trials for acute myelogenous leukemia and myelodysplastic syndrome. Additionally, ChemGenex is developing Quinamed, which is in Phase 2 clinical trials for hormone refractory prostate cancer. The company, formerly known as AGT Biosciences Limited, rebranded in June 2004 to reflect its focus on oncology therapeutics.

Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. They are focused on addressing unmet needs in the field of cancer with the development of hypoxia-activated prodrugs that target cancer cells. Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University. Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland. PR610 is the lead compound from their pipeline of pro-drugs based on hypoxia-activated tyrosine-kinase inhibitors. These pro-drugs selectively release active tyrosine-kinase inhibitors within the low-oxygen (hypoxic) environment found in many solid tumors. By shifting the release of active drug away from normal tissues and into cancer tissues, these drugs are predicted to be more effective and less toxic than currently available therapies. To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.

Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications. Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.

Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. They are focused on addressing unmet needs in the field of cancer with the development of hypoxia-activated prodrugs that target cancer cells. Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University. Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland. PR610 is the lead compound from their pipeline of pro-drugs based on hypoxia-activated tyrosine-kinase inhibitors. These pro-drugs selectively release active tyrosine-kinase inhibitors within the low-oxygen (hypoxic) environment found in many solid tumors. By shifting the release of active drug away from normal tissues and into cancer tissues, these drugs are predicted to be more effective and less toxic than currently available therapies. To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.

Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

OPAL Therapeutics Pty Limited operates as an immunotherapy development company in Australia. It develops therapies for the treatment of human immunodeficiency virus, Hepatitis C, and chronic infection. OPAL Therapeutics Pty Limited was incorporated in 2005 and is based in Melbourne, Australia.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Hatchtech is an Australian company focused on developing innovative pest control solutions through its proprietary technology platform. The company's patented approach targets the egg hatch of pest species, effectively disrupting their lifecycle with a novel mode of action. Hatchtech's technology is designed to address various invertebrate pests, including ectoparasites such as head lice, as well as pests affecting animals, crops, and the built environment. Their flagship product offers a single-dose treatment that eliminates both head lice and their eggs in one application, providing an effective solution for infestations.

Humanigen, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, that specializes in the development of proprietary monoclonal antibodies aimed at immunotherapy and oncology treatments. The company’s leading candidate, Lenzilumab, targets granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I portion of a Phase I/II clinical trial for various hematologic malignancies. The company is also working on HGEN005, an anti-EMR1 monoclonal antibody in the pre-clinical stage for eosinophilic diseases. Humanigen has established collaborations, including a clinical partnership with Kite Pharma to study Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma and a research agreement with the Department of Defense to facilitate the development of Lenzilumab for potential emergency use in COVID-19. Formed in 2000, the company was previously known as KaloBios Pharmaceuticals and rebranded as Humanigen in 2017.

Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. They are focused on addressing unmet needs in the field of cancer with the development of hypoxia-activated prodrugs that target cancer cells. Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University. Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland. PR610 is the lead compound from their pipeline of pro-drugs based on hypoxia-activated tyrosine-kinase inhibitors. These pro-drugs selectively release active tyrosine-kinase inhibitors within the low-oxygen (hypoxic) environment found in many solid tumors. By shifting the release of active drug away from normal tissues and into cancer tissues, these drugs are predicted to be more effective and less toxic than currently available therapies. To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.